# A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.

> **NCT00405119** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 92 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Reflux, Gastroesophageal

## Interventions

- **DRUG:** AH23844 (lavoltidine)
- **DRUG:** NEXIUM (esomeprazole)
- **DRUG:** ZANTAC (ranitidine)

## Key facts

- **NCT ID:** NCT00405119
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405119, "A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00405119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*